激光治疗视网膜静脉阻塞疗效分析

目的 评价激光在治疗视网膜静脉阻塞中的作用和疗效。方法 使用美国HGM M－5氩氪激光机、日本Nidek GYC-2000倍频532激光机及法国光太（BIV）VIRIDIS－LIET 532激光机对112例视网膜中央或分支静脉阻塞的患者进行光凝治疗。随访6－18个月，对比分析光凝前后视力、眼底及眼底荧光血管造影（FFA）结果的变化情况。结果 36眼缺血型视网膜中央静脉阻塞中22眼有效，占61．11％；6眼好转，占16．67％；8眼因玻璃体出血、继发青光眼或并发白内障失明而无效，占22．22％；76眼视网膜分支静脉阻塞中59眼有效，占77．63％；13眼好转，占17．11％；4眼无效，占5．26％，总有效率达72．32％。视力提高的84眼，占75％。结论 激光光凝术对治疗视网膜静脉阻塞有显著疗效。     

Vitrectomy for nondiabetic vitreous hemorrhage. Retinal and choroidal vascular disorders

The results and complications of pars plana vitrectomy for nondiabetic vitreous hemorrhage due to retinal and choroidal vascular disorders were studied in 68 eyes of 66 patients. Diagnoses included: retinal branch vein obstruction (34 eyes), choroidal neovascularization (15 eyes), central retinal vein occlusion (5 eyes), Eales' disease (10 eyes), pars planitis (3 eyes), and hemoglobin S-C retinopathy (1 eye). The duration of the vitreous hemorrhage was 6 months or more in 48 eyes (71%), and averaged 17.8 months. Preoperative visual acuity was less than 5/200 in 57 eyes (84%). Best postoperative visual acuity was 5/200 or better in 55 patients (81%), and vision improved two or more lines after vitrectomy in 54 eyes (80%). Patients with retinal branch vein obstruction, Eales' disease, or pars planitis had the best prognosis. Those with central retinal vein obstruction or choroidal neovascularization had the worst prognosis.     

Radial optic neurotomy (RON) for central retinal vein occlusion

BACKGROUND: Compression in the lamina cribrosa is discussed as a reason for central retinal vein occlusion. Radial optic neurotomy should release the pressure and increase venous blood outflow. PATIENTS AND METHODS: In a clinical trial 27 eyes with central retinal vein occlusion (22 eyes with clinical ischaemia, 5 eyes with continuous disc oedema and visual acuity below 4/10) underwent surgical decompression by vitrectomy and radial optic neurotomy. During surgery the intravenous pressure in the central vein was tested by infusion dynamometry before and right next to the incision. Follow up-time minimally was 1.5 years. RESULTS: Infusion dynamometry demonstrated a decrease of the central vein pressure right next to the incision in all eyes. In 17/22 eyes with ischaemic type of occlusion 6 weeks after surgery the relative afferent pupillary defect was lowered significantly and no growth of neovascularisations occurred. 5 eyes with persistence of the afferent pupillary defect received laser/cryocoagulation because of neovascularisations. After surgery visual acuity improved in 20/27 eyes and remained unchanged in 4/27 eyes. As complications we saw small subretinal haemorrhages at the neurotomy site (5/27), vitreous haemorrhages (7/27), hypotonia and choroidal detachment (1/27) and segmental visual field loss (14/27). CONCLUSIONS: The results of infusion dynamometry strongly support the hypothesis of a postulated compression of the central retinal vein in the lamina cribrosa. Functional results of radial optic neurotomy are superior to those of the natural course of ischaemic retinal vein occlusion in the literature, but visual field defects in association with the neurotomy site seem to be a serious side-effect of this therapeutic approach.     

Outcomes of vitreoretinal surgery for complications of branch retinal vein occlusion

OBJECTIVE: To investigate outcomes of vitreoretinal surgery for complications of branch retinal vein occlusion (BRVO). DESIGN: Retrospective, noncomparative case series. PARTICIPANTS: The medical records of all patients who underwent vitreoretinal surgery for complications of BRVO at Bascom Palmer Eye Institute between January 1, 1991 and December 31, 1998 were reviewed. Thirty-six eyes from 36 consecutive patients were identified. MAIN OUTCOME MEASURES: Visual acuity outcomes include preservation of preoperative visual acuity and visual acuity greater than or equal to 20/40, 20/200 and 5/200. When preoperative retinal detachment was present, the anatomic outcome assessed was complete retinal attachment. Postoperative event rates of retinal detachment, vitreous hemorrhage, epiretinal membrane (ERM), and cataract were tabulated. All outcomes were assessed at 6 months. RESULTS: Surgical indications included nonclearing vitreous hemorrhage (17 patients), traction retinal detachment involving the macula (15), and ERM (4). Mean follow-up was 19 months. Preoperatively, best-corrected vision was greater than or equal to 20/200 in 19/36 (53%) eyes. Six months postoperatively, best-corrected vision was greater than or equal to 20/40 in 12/36 (33%) eyes, greater than or equal to 20/200 in 27/36 (75%) eyes, and greater than or equal to 5/200 in 31/36 (86%) eyes. Postoperative complications included retinal detachment (2/36; 6% eyes), ERM (3; 8%), vitreous hemorrhage (2; 6%), suprachoroidal hemorrhage (1; 3%), central retinal vein occlusion (1; 3%), and central retinal artery occlusion (1; 3%). Clinical features associated with better visual outcome include better preoperative visual acuity (P: = 0.05), absence of preoperative afferent pupillary defect (P: = 0.01), and absence of preoperative macular edema (P: = 0.08). CONCLUSIONS: Following surgery, retinal attachment and improved visual acuity were achieved in the majority of patients. Pre-existing pathology and postoperative complications may limit final vision in eyes with BRVO.     

视网膜中央静脉阻塞玻璃体积血合并原发性高血压的手术疗效

目的:分析视网膜中央静脉阻塞玻璃体积血合并原发性高血压的手术疗效.方法:回顾性分析2011-03/2015-03因玻璃体积血在我院行玻璃体切割的原发性高血压患者83例83眼,根据术中所见,其中有28眼玻璃体积血由视网膜中央静脉阻塞引起,术后随访9~36(平均22.4)mo.检查记录患者手术前后最佳矫正视力、术后并发症情况,并进行统计分析.结果:视网膜中央静脉阻塞玻璃体积血合并原发性高血压发生率为33.7%;术后最佳矫正视力3.3~4.5,术后最佳矫正视力提高24眼(86%),视力不变4眼(14%),无视力下降患者,手术前后视力相比差异有统计学意义(P<0.05);术后发生黄斑水肿5眼,发生率18%;所有患者术后均没有发生视网膜脱离及复发玻璃体积血.结论:手术治疗合并原发性高血压的视网膜中央静脉阻塞玻璃体积血疗效好,可减少并发症,提高视力.     

Radial optic neurotomy as treatment for central retinal vein occlusion

PURPOSE: To review our initial experience with radial optic neurotomy as treatment for retinal vein occlusion. DESIGN: Interventional case series. METHODS: Patient population: five patients (four with central retinal vein occlusion and one with hemiretinal vein occlusion). INTERVENTION: Pars plana vitrectomy with radial optic neurotomy was performed in each case. MAIN OUTCOME MEASURES: Best-corrected visual acuity, presence of macular edema, perfusion status, and time to venous phase of the angiogram were reviewed retrospectively. RESULTS: Mean preoperative visual acuity was 4/200. Preoperatively, the vein occlusion was perfused in one (20%), nonperfused in one (20%), and indeterminate in three (60%). Mean follow-up time was 4.5 months. Mean postoperative visual acuity was 20/400 at last follow-up. Four patients (80%) had improvement in visual acuity and one (20%) worsened. Two patients (40%) improved to 20/80 postoperatively. In four cases (80%), disk congestion improved and intraretinal hemorrhage reabsorbed more quickly than would be expected without treatment. Time to the venous phase of fluorescein angiography improved slightly in three cases (60%) postoperatively. Perfusion status as determined by fluorescein angiography was not significantly altered postoperatively. One patient (20%) had resolution of macular edema postoperatively as shown by volumetric optical coherence tomography. One patient developed choroidovitreal neovascularization and one developed iris neovascularization postoperatively, both of which responded to panretinal photocoagulation. CONCLUSIONS: Radial optic neurotomy may improve visual acuity in eyes with central retinal vein occlusion, although choroidovitreal neovascularization from the neurotomy site can occur. Further study is needed to determine its role in the management of central vein occlusion.     

Retinal endovascular surgery and intravitreal triamcinolone acetonide for central vein occlusion in young adults

PURPOSE: To report the results of retinal endovascular surgery and intravitreal triamcinolone acetonide on two eyes of two patients younger than 40 years of age with central vein occlusion. DESIGN: Interventional case reports from a study approved by the Institutional Review Board of North Broward Medical Center, Pompano Beach, Florida. METHODS: Two men, ages 37 and 39, with unilateral central vein occlusion were treated with retinal endovascular surgery and intravitreal triamcinolone acetonide. The main outcome measure was recovery of visual acuity. RESULTS: One patient recovered 8 lines of visual acuity, the other recovered 11 lines. There was rapid clearance of intraretinal hemorrhage and edema in both cases. CONCLUSIONS: Retinal endovascular surgery and intravitreal triamcinolone acetonide may promote recovery of visual acuity in eyes of young adults with central vein occlusion.     

Retinal surgery for treatment of central retinal vein occlusion

Vitreous surgery with retinal vein cannulation and injection of tissue plasminogen activator was performed in 8 eyes of 8 patients with longstanding visual loss secondary to central retinal vein occlusion. A modest improvement in visual acuity was demonstrated in 4 of the 8 eyes, and 3 of the 8 eyes maintained the preoperative vision. Retinal vein cannulation may offer a new treatment option for patients with central retinal vein occlusion.     

Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion

PURPOSE: To evaluate treatment of cystoid macular edema associated with central retinal vein occlusion with intravitreal triamcinolone acetonide. METHODS: This study included 10 eyes of nine patients with perfused central retinal vein occlusion with visual acuity of 20/50 or worse. Following baseline evaluation, including best-corrected visual acuity, intraocular pressure (IOP), fluorescein angiography, and volumetric optical coherence tomography (VOCT), triamcinolone acetonide (4 mg in 0.1 ml) was injected into the vitreous cavity. RESULTS: Mean duration from the time of diagnosis to the intravitreal injection was 15.4 months. All 10 eyes demonstrated biomicroscopic improvement in cystoid macular edema with corresponding improvement in VOCT measurements from a mean of 4.2 mm(3) preinjection to a mean of 2.6 mm(3) at last follow-up (P <.001). Mean best-corrected visual acuity improved from 58 letters (range, 37-72) at baseline to 78 letters (range, 50-100 letters) at last follow-up (average, 4.8 months). The visual acuity improvement was statistically significant (P =.01). Six eyes (60%) were > or =20/50. There were no significant complications. Three eyes (30%) without previous history of glaucoma required initiation of topical aqueous suppressant therapy for IOP elevation at last follow-up. One eye with a previous history of open-angle glaucoma required a trabeculectomy. CONCLUSIONS: Intravitreal injection of triamcinolone acetonide appears to be effective in reducing cystoid macular edema associated with central retinal vein occlusion. This reduction often corresponded to an improvement in visual acuity. Further evaluation is warranted to assess its safety and efficacy in these eyes.     

Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion

PURPOSE: To assess the efficacy of intravitreal triamcinolone treatment for macular edema from central retinal vein occlusion (CRVO) and hemiretinal vein occlusion (HRVO). METHODS: This study was a retrospective medical records review of 24 eyes of 24 patients (mean age, 71 years) that were injected with 4 mg of intravitreal triamcinolone acetonide for treatment of macular edema due to CRVO (n = 21) and HRVO (n = 3). Of the 24 eyes, 14 were injected once, 6 were injected twice, 3 were injected 3 times, and 1 received 4 injections. Mean follow-up time was 10 months (range, 3-24 months). The average time between onset of symptoms and first injection was 5.4 months (range, 2-48 months). Available documents on pre- and postinjection optical coherence tomography central foveal thickness in 23 of 39 total injections were evaluated. RESULTS: All injections resulted in reduction in central foveal thickness as determined by optical coherence tomography. The mean central foveal thickness decreased to 55% of preinjection values ([n = 23] 635 vs. 352 mum, respectively; P < 0.001). The average gain in visual acuity was 1.3 Snellen lines (range, -3-7) over the course of the study period. Ten eyes gained > or =2 lines of visual acuity, 3 eyes improved 1 line, 7 eyes remained the same, and 4 eyes worsened. There was no correlation between improvement in foveal thickness and corresponding visual gain (P = 0.24). None of the eyes of diabetic patients (n = 6) or patients with ischemic CRVO (n = 2) improved in visual acuity. The difference in mean baseline (20/167) and mean final visual acuity (20/91) was statistically significant (P = 0.015). The mean best postinjection visual acuity (20/67) was also significantly higher than the mean final visual acuity (P = 0.019). When diabetic and ischemic CRVO patients were excluded, the difference between mean baseline visual acuity and mean final visual acuity was found to be highly significant ([n = 16] 20/133 vs. 20/67, respectively; P < 0.001), while mean final and best postinjection visual acuities (20/50) did not differ (P = 0.085). Eight of 16 phakic eyes showed progression of cataract, 2 of which underwent cataract extraction. Nine of 18 patients without a history of glaucoma developed ocular hypertension and required glaucoma medication during postinjection follow-up. Trabeculectomy was performed on two eyes with glaucoma. Two other eyes developed epiretinal membranes, one of which underwent vitrectomy. CONCLUSIONS: Intravitreal triamcinolone may be effective in treating macular edema from CRVO and HRVO. Subjects with concurrent diabetes or ischemic central retinal vein were less likely to have visual improvement.     

Intravitreal tissue plasminogen activator for acute central retinal vein occlusion.

OBJECTIVES: We investigated the efficacy of intravitreal tissue plasminogen activator (tPA) for the treatment of acute central retinal vein occlusion. DESIGN: Twenty-six eyes with central retinal vein occlusion (CRVO, n=23) and hemi-retinal vein occlusion (n=3) with recent onset of visual symptoms (< or = 21 days) were identified and given an intravitreal injection of 65 -110 microg of tPA. RESULTS: Among eyes with CRVO, visual acuity improved to > or = 20/40 in 7 of 23 patients (30.4%) at 6 weeks, and 8 of 23 patients (34.8%) at 6 months. Visual acuity improved or stabilized in 69.6% (16 of 23 patients) at the 6 week visit and persisted with longer follow-up. Four patients developed doubling of the visual angle. No patients developed rhegmatogenous retinal detachment, infection or neovascular glaucoma. One patient developed a small vitreous hemorrhage and 2 developed an increase in the size of pre-existing macular hemorrhage. CONCLUSION: Intravitreal tPA administered early in the course of central retinal vein occlusion did not lead to catastrophic hemorrhagic events. Intravitreal tPA may cause worsening of vision in some patients. While some eyes appear to have benefited from the therapy, no conclusions can be reached because there was not a concurrent control group. A randomized clinical trial is necessary to determine its efficacy. SUMMARY STATEMENT: Intravitreal tPA administered early in the course of central retinal vein occlusion did not lead to catastrophic hemorrhagic events. A randomized clinical trial is necessary to determine its efficacy.     

激光诱导脉络膜视网膜静脉吻合术对非缺血型视网膜静脉阻塞所致黄斑水肿的疗效观察

目的 观察激光诱导脉络膜视网膜静脉吻合术治疗非缺血型视网膜静脉阻塞（retinal vein occlusion,RVO）所致黄斑水肿的疗效。 方法 非缺血型RVO患者37例37只黄斑水肿眼均使用氪红激光诱导脉络膜视网膜静脉吻合，吻合术后随访6~12个月(平均随访9个月)，对比分析建立和未建立脉络膜视网膜静脉吻合的眼治疗前后视力、眼底、荧光素眼底血管造影（fundus fluorescein angoigraphy, FFA）、中心5°视网膜光敏感度的改变。 结果 37只眼中，激光治疗后2个月内有18只眼建立脉络膜视网膜静脉吻合，成功率48.6%。建立与未建立脉络膜视网膜静脉吻合的眼，治疗前后平均最佳矫正视力差异有显著性意义（P＜0.001）。建立吻合的眼，中心5°光敏感度与治疗前相比有明显提高（t=2.910, P＜0.005）；FFA显示16只眼黄斑水肿消失或减轻，2只眼黄斑囊样水肿仍存在。未建立吻合的眼，中心5°光敏感度与治疗前相比有所下降（t=1.928, P＜0.05），FFA显示黄斑水肿加重。 结论 RVO所致黄斑水肿未发展至囊样变性之前，激光诱导建立脉络膜视网膜静脉吻合可使RVO所致黄斑水肿消退或减轻，从而改善视功能。 （中华眼底病杂志，2002，18：10-12）     

缺血型视网膜中央静脉阻塞的氪离子激光治疗

目的 探讨缺血型视网膜中央静脉阻塞的氪离子激光治疗的疗效.方法 回顾性分析我院应用氪激光全视网膜光凝治疗的缺血型中央静脉阻塞102眼的临床资料.结果 102眼缺血型视网膜中央静脉阻塞中73眼有效,占71.56%;27眼好转,占26.47%;2眼因玻璃体出血,继发新生血管性青光眼或并发白内障失明而无效,占1.97%.结论 对于缺血型视网膜中央静脉阻塞的患者应尽早实行全视网膜光凝术治疗,确保有效光斑的总数与密度是全视网膜光凝术成功的关键.     

Retinal blood flow and macular edema after radial optic neurotomy for central retinal vein occlusion

PURPOSE: To determine the effect of radial optic neurotomy (RON) on retinal blood flow (RBF) and macular edema in eyes with a central retinal vein occlusion. DESIGN: Prospective interventional study. METHODS: Seven eyes of seven patients with central retinal vein occlusion underwent RON and vitrectomy and were followed for at least 6 months. The RBF was calculated from dye dilution curves of video fluorescein angiograms. The foveal thickness was determined by optical coherence tomography. RESULTS: At 1 week after surgery, the RBF was significantly reduced from 28.5 +/- 5.4 to 21.1 +/- 6.6 pixel(2)/s (P < .01). At 6 months after surgery, the RBF (26.0 +/- 7.7 pixel(2)/s) was not significantly different from the preoperative RBF, although chorioretinal anastomoses were found in all seven eyes. The foveal thickness was significantly decreased from 711 +/- 271 to 488 +/- 182 mum (P = .03). The postoperative visual acuity was better than the preoperative visual acuity by two or more lines in three out of seven eyes, and was worse in two eyes. CONCLUSIONS: Neither RON nor chorioretinal anastomoses improved the RBF but macular edema was improved. These findings suggest that removal of the vitreous could reduce macular edema as in diabetic macular edema. However, we cannot exclude the possibility that the changes represent the natural course of this disease.     

Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide

PURPOSE: To evaluate the effect of intravitreal triamcinolone acetonide on visual acuity in branch retinal vein occlusion. METHODS: The prospective comparative nonrandomized clinical interventional study included 28 patients (28 eyes) with branch retinal vein occlusion. The study group consisting of 10 consecutive patients received an intravitreal injection of 20-25 mg of triamcinolone acetonide. The control group including 18 patients did not receive an intravitreal injection. The mean follow-up was 8.7+/-4.4 months. RESULTS: In the study group, mean visual acuity increased significantly (P=0.02) from 0.27+/-0.11 preoperatively to a best postoperative visual acuity of 0.45+/-0.27. Visual acuity measurements determined 1 month after the injection were significantly (P=0.027) higher than baseline values. Nine (90%) eyes gained in visual acuity, with six (60%) eyes showing an increase in visual acuity of at least two Snellen lines. In the ischaemic subgroup, visual acuity did not change significantly (0.18+/-0.18 to 0.13+/-0.04; P=0.66), while, in the nonischaemic subgroup, visual acuity increased significantly (P=0.012) from the baseline value to the best postoperative measurement (0.29+/-0.09 to 0.53+/-0.24). In the control group, baseline visual acuity and best visual acuity during the follow-up did not vary significantly (P=0.27). Comparing the study and control groups with each other, the gain in visual acuity was significantly higher in the study group at 1 month (P=0.016) and 2 months (P=0.012) after baseline. CONCLUSIONS: Intravitreal injection of triamcinolone acetonide can increase visual acuity in patients with branch retinal vein occlusion.     

The effect of age and initial visual acuity on the systemic and visual prognosis of central retinal vein occlusion

Papillophlebitis is the term that is often used to describe a central retinal vein occlusion with preserved visual acuity in a young, healthy patient. Among 194 patients with a diagnosis of central retinal vein occlusion (CRVO), 19 patients were identified who were under 50 years of age and who had visual acuity of 6/12 or better in the affected eye. These patients retained good vision in the affected eye during the course of the disorder with 17 eyes returning to 6/6. All of these patients remained healthy over a mean follow-up period of about four years. This group of patients was compared to a second group of 28 patients who also were under 50 years of age, but who had initial visual acuity in the affected eye less than 6/12. These patients had a variable visual outcome. In addition, they had a higher prevalence of systemic hypertension over the follow-up period than did a group of age-matched control subjects. An additional comparison was made to a group of 26 patients with visual acuity of 6/12 or better in the affected eye but who were over 50 years of age. Forty-six per cent of these patients had final visual acuity less than 6/12, and they had a higher prevalence of systemic vascular disease than did a group of age-matched control subjects.     

Radial optic neurotomy for severe central retinal vein occlusion: preliminary results

PURPOSE: To describe the results of radial optic neurotomy for the treatment of severe central retinal vein occlusion. PATIENTS AND METHODS: Prospective noncomparative single-center study. Analysis of ten eyes of ten consecutive patients whose visual acuity was 0.1 or less. They underwent fluorescein angiography, visual field testing by automated perimetry, and macular thickness analysis by optical coherence tomography preoperatively at 3 months and at 6 months postoperatively. RESULTS: Mean visual acuity on an ETDRS chart increased from 30+/-12 points preoperatively to 42+/-15 points at the 3-month visit, (p=0.03), and mean macular thickness decreased from 580+/-150 micro m to 361+/-52 micro m (p=0.04). All patients had clinical improvement as determined by fundus examination and fluorescein angiography. An improvement in the central visual field was observed in all eyes. Mean visual acuity of the five patients followed-up for 6 months was 52.8+/-20 points. No visual loss was observed. None of the patients underwent laser photocoagulation or has presented with neovascularization so far. Optociliary veins developed in three eyes and a retinochoroidal anastomosis within the disk incision was observed in two eyes. CONCLUSION: These preliminary results are encouraging when compared to the reported natural progression of severe central retinal vein occlusion. A bypass of the site of occlusion is a possible mechanism for radial optic neurotomy. A randomized study should be conducted to assess the efficacy of radial optic neurotomy and determine the best candidates for surgery.     

The effect of age and initial visual acuity on the systemic and visual prognosis of central retinal vein occlusion

Papillophlebitis is the term that is often used to describe a central retinal vein occlusion with preserved visual acuity in a young, healthy patient. Among 194 patients with a diagnosis of central retinal vein occlusion (CRVO), 19 patients were identified who were under 50 years of age and who had visual acuity of 6/12 or better in the affected eye. These patients retained good vision in the affected eye during the course of the disorder with 17 eyes returning to 6/6. All of these patients remained healthy over a mean follow-up period of about four years. This group of patients was compared to a second group of 28 patients who also were under 50 years of age, but who had initial visual acuity in the affected eye less than 6/12. These patients had a variable visual outcome. In addition, they had a higher prevalence of systemic hypertension over the follow-up period than did a group of age-matched control subjects. An additional comparison was made to a group of 26 patients with visual acuity of 6/12 or better in the affected eye but who were over 50 years of age. Forty-six per cent of these patients had final visual acuity less than 6/12, and they had a higher prevalence of systemic vascular disease than did a group of age-matched control subjects.     

玻璃体腔注射曲安奈德减轻视网膜静脉阻塞继发的黄斑水肿

目的:评估玻璃体腔内注射曲安奈德(triamcinolone acetonide,TA)治疗视网膜静脉阻塞(retinal vein occlusion,RVO)引起的黄斑水肿的长期安全性与有效性。方法:患者17例17眼出现视网膜静脉阻塞引起的黄斑水肿,接受玻璃体腔内注射2mgTA,随访1a,监测患者视力、黄斑厚度。结果:随访发现,15眼(88%)视力得到明显改善,从术前0.114±0.068增加到术后的0.184±0.094,差异有统计学意义(P<0.05),而中央黄斑区的厚度从术前的514.0±67.4μm减少到术后的442.0±61.5μm,差异有统计学意义(P<0.05)。术后6例患者出现短期眼压升高,并无并发性白内障,玻璃体出血,视网膜脱离以及眼内炎的发生。结论:玻璃体腔内注射TA能长期有效减缓RVO引起的黄斑水肿。     

Comparative study on efficacy of a combination therapy of triamcinolone acetonide administration with and without vitrectomy for macular edema associated with branch retinal vein occlusion

AIMS: To compare the efficacy ofa combination therapy of triamcinolone acetonide (TA) administration with and without vitrectomy in eyes with macular edema associated with branch retinal vein occlusion over a 1-year period. METHODS: A retrospective, case-control study was conducted in 15 eyes of 15 patients with macular edema associated with branch retinal vein occlusion. Eight eyes underwent simultaneous intravitreal and posterior sub-Tenon capsule injections of TA (TA-injected group). Seven eyes underwent vitrectomy with intravitreal or simultaneous posterior sub-Tenon capsule injection of TA (vitrectomy with TA group). Macular thickness and visual acuity were measured before and at 1, 3, 6 and 12 months after the therapy. RESULTS: Twelve months after the therapy, mean visual acuity improved significantly from baseline in both the TA-injected (p = 0.0069) and vitrectomy with TA groups (p = 0.0145). Macular thickness also improved significantly in both the TA-injected (p = 0.0065) and vitrectomy with TA groups (p = 0.0058). At 12 months after the therapy, there was no significant difference in visual acuity and macular thickness between the two groups (p = 0.3308 and 0.3711, respectively). At the early postoperative stage (1 and 3 months after the therapy), the central macular thickness in the TA-injected group was significantly less than that in the vitrectomy with TA group (p = 0.0140 and 0.0275, respectively); there was no significant difference in visual acuity between the two groups (p = 0.0796 and 0.3753, respectively). CONCLUSION: TA injection without vitrectomy was as effective as a combination therapy of TA injection with vitrectomy.